• Explore /
  • Poster
  • / Five-year overall survival with S-1 plus docetaxel as adjuvant treatment in curatively resected pStage III gastric cancer in JACCRO GC-07.

Five-year overall survival with S-1 plus docetaxel as adjuvant treatment in curatively resected pStage III gastric cancer in JACCRO GC-07.

Abstract Poster

Authors

null

Wataru Ichikawa

Division of Medical Oncology, Showa University Fujigaoka Hospital, Yokohama, Japan

Wataru Ichikawa , Kazuhiro Yoshida , Yasuhiro Kodera , Masato Kitazawa , Motohiro Hirao , Yasuyuki Seto , Kenji Hibi , Shinichi Kinami , Masaya Watanabe , Shigeto Makino , Mitsugu Kochi , Takeshi Sano , Yoshihiro Kakeji , Masahiro Takeuchi , Masashi Fujii

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer - Local-Regional Disease

Clinical Trial Registration Number

UMIN 000010337

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 4065)

DOI

10.1200/JCO.2023.41.16_suppl.4065

Abstract #

4065

Poster Bd #

386

Abstract Disclosures

Similar Posters

First Author: Hiromichi Miyagaki

First Author: Rixci Ramirez

First Author: Jian Xiao

Poster

2024 ASCO Gastrointestinal Cancers Symposium

Randomized phase II study comparing neoadjuvant FLOT versus DOS for patients with type 4 or large type 3 gastric cancer (JCOG2204).

Randomized phase II study comparing neoadjuvant FLOT versus DOS for patients with type 4 or large type 3 gastric cancer (JCOG2204).

First Author: Izuma Nakayama